Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment with a current market capitalization of $803 million, has been making ...

Headquartered in Shenzhen, China, Synthetica is a biotech company founded in 2023 ... Our innovative synthetic biology approach to developing oncolytic bacteria offers new hope for more effective ...

More information: Yamato Goto et al, Discovery of Intratumoral Oncolytic Bacteria Toward Targeted Anticancer Theranostics, Advanced Science (2023). DOI: 10.1002/advs.202301679 ...

CORAL GABLES, FLORIDA, UNITED STATES, February 1, 2023 /EINPresswire.com/ -- Adze Biotechnology Granted Patent for its Proprietary Oncolytic Adenovirus Platform. Adze ...

Genelux Corporation (NASDAQ:GNLX) has made great progress in advancing the use of oncolytic virus-based immunotherapy ... who runs the Biotech Analysis Central pharmaceutical service on Seeking ...

This method enhances its capability to target metastatic cancers effectively, a significant advantage over other oncolytic viruses. Oncolytics Biotech is also progressing towards pivotal clinical ...

Called ONCOTECH, it combines oncolytic virotherapy and adoptive T cell therapy for treatment of patients with cancerous tumors. The study is published in the journal Nature Biotechnology.

The research article, “An oncolytic virus–T cell chimera for cancer immunotherapy,” was published in Nature Biotechnology. Among the newer forms of immunotherapy for cancer treatment ...

SAN DIEGO and CALGARY, AB, April 10, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discussed ...

This complimentary report offers biotech and pharmaceutical companies, data-driven analysis to navigate the complexities of clinical trials and regulatory frameworks in oncolytic virus therapy.

Despite skepticism about oncolytic viruses, Replimune's approach and collaborations with big pharma could yield significant commercial opportunities if clinical data remains strong. Biotech ...